Re: Olaparib for Metastatic Castration-resistant Prostate Cancer.
暂无分享，去创建一个
[1] F. Saad,et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[2] P. Kantoff,et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. , 2020, European urology.
[3] N. Lawrentschuk,et al. Where to Next for Theranostics in Prostate Cancer? , 2019, European urology oncology.
[4] D. Murphy,et al. Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics. , 2019, European urology.
[5] M. Rubin,et al. Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study , 2018, European urology.
[6] Thomas Wiegel,et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. , 2018, European urology.
[7] R. Bristow,et al. The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer. , 2017, European urology.
[8] Colin C Pritchard,et al. DNA Repair in Prostate Cancer: Biology and Clinical Implications. , 2017, European urology.
[9] Wei Yuan,et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.